Nimotuzumab: Phase III discontinued

In April, Daiichi Sankyo discontinued a double-blind, placebo-controlled, Japanese Phase III trial evaluating IV nimotuzumab with concurrent chemoradiotherapy as first-line treatment of unresectable and locally advanced squamous cell lung

Read the full 291 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE